This article is for information and discussion purposes only and does not form a recommendation to invest or otherwise. The value of an investment may fall. The investments referred to in this article may not be suitable for all investors, and …
But the biggest dividend among Big Pharma stocks belongs to GlaxoSmithKline PLC (NYSE:GSK). The Brentford, England-based company’s 5% dividend yield stands well above other health care giants such asJohnson & Johnson …
“They are getting more specialized, but it’s still the primary care that is facing more pricing pressure,” said Evans, who has a hold rating on GSK’s stock. The challenge for GSK going forward is to diversify its revenue sources to offset the sales ...
So far GlaxoSmithKline plc (ADR) (NYSE:GSK)’s stock price appears to be unaffected by the news, and there is not much concern that the investigation will seriously harm the company’s profits. Even if this is the beginning of a difficult …
Century Aluminum (NASDAQ:CENX): JP Morgan moves the stock to Underweight from Neutral. GlaxoSmithKline (NYSE:GSK): Pharmaceutical giant GlaxoSmithKline sees its stock downgraded to Hold from Buy at Deutsche …
Sharekhan has a buy call on GlaxoSmithKline Consumer Healthcare with a target price of Rs 7,310 ... Chocolate Horlicks will remain the key growth drivers in the long run. The stock is trading at a discounted valuation of nearly 30x …
LONDON (Reuters) - Britain's Orchard Therapeutics, which has already raised more than $140 million (98.54 million pounds) to fund its work in gene therapy, plans another private sale of shares following its acquisition of a portfolio of …
GSK stock rose after news of the settlement, climbing 1.6% to a share price of $46.30 in late afternoon trading on the New York Stock Exchange.
GSK shares fell 1.6% to 1,466 pence as of 10.18am in London trading. That extended the stock’s decline this year to 9%. GSK is trying to establish new respiratory drugs in the US to help replace the lost sales of Advair. “Retail sales teams …
they can easily earn 20 percent per annum on the stock,” she adds. On the valuation front, the GSK stock—at the buyback price—would trade at around 34 times the current year (2014) estimated earnings, Angel Broking analysts …